Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study
Mads Israelsen, Nikolaj Torp, Stine Johansen, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 3, pp. 218-228
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 314
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 59
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 36
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 30
Metabolic Dysfunction and Alcohol-related Liver Disease (MetALD): Position statement by an expert panel on alcohol-related liver disease
Juan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 23
EASL position paper on clinical follow-up after HCV cure
Thomas Reiberger, Sabela Lens, Giuseppe Cabibbo, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 326-344
Closed Access | Times Cited: 22
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
Brian P. Lee, Katie Witkiewitz, Jessica L. Mellinger, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 9, pp. 626-645
Open Access | Times Cited: 20
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Maja Thiele, Ida Falk Villesen, Lili Niu, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 345-359
Open Access | Times Cited: 16
Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence
Stefano Ciardullo, Alessandro Mantovani, Mario Luca Morieri, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1762-1767
Closed Access | Times Cited: 16
Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
Federica Tavaglione, Maral Amangurbanova, Alexander H. Yang, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 9
Clinical Trial to Assess the Safety and Tolerability of Anti‐IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease
Luis Antonio Díaz, Sheldon Morris, Shravan Dave, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 2
Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Impacts Long‐Term Outcomes After Curative‐Intent Surgery for Hepatocellular Carcinoma
Deniz Uluk, Justus Pein, Stefanie Herda, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 2
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 2
Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA
Alexander H. Yang, Monica A. Tincopa, Federica Tavaglione, et al.
Gut (2024) Vol. 73, Iss. 12, pp. 2045-2053
Open Access | Times Cited: 14
Envisioning how to advance the MASH field
Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, et al.
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 13
Metabolic characteristics of patients with MetALD: Caveats of a new definition
Erin Petrie, Meagan Gray, Fernando Bril
Liver International (2024) Vol. 44, Iss. 11, pp. 2929-2938
Closed Access | Times Cited: 12
Non-invasive tests for alcohol-associated liver disease
Mads Israelsen, Wiramon Rungratanawanich, Maja Thiele, et al.
Hepatology (2024) Vol. 80, Iss. 6, pp. 1390-1407
Closed Access | Times Cited: 10
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
Clémence M. Canivet, Jérôme Boursier, Rohit Loomba
Seminars in Liver Disease (2024) Vol. 44, Iss. 01, pp. 035-042
Closed Access | Times Cited: 9
MOVING DIAGNOSIS OF LIVER FIBROSIS INTO THE COMMUNITY
Elisa Pose, Salvatore Piano, Maja Thiele, et al.
Journal of Hepatology (2025)
Closed Access | Times Cited: 1
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?
Konstantinos Arvanitakis, Theocharis Koufakis, Εvangelos Cholongitas, et al.
Pharmacology & Therapeutics (2025), pp. 108811-108811
Open Access | Times Cited: 1
Editorial: Lipidomics in MASLD and MetALD
Rajalakshmi Govalan, Vincent Chen
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
MetALD: Does it require a different therapeutic option?
George Marek, Harmeet Malhi
Hepatology (2024) Vol. 80, Iss. 6, pp. 1424-1440
Closed Access | Times Cited: 8
Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry
Pedro Ochoa‐Allemant, Marina Serper, Roy Wang, et al.
Hepatology (2024)
Closed Access | Times Cited: 7
Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region
Pojsakorn Danpanichkul, Kanokphong Suparan, Banthoon Sukphutanan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance
Takao Miwa, Yuki Utakata, Tatsunori Hanai, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 849-857
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top